Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifebemtinib combination therapy in advanced solid tumors
NCT05830539Phase 2Completed
- Sponsor
- InxMed
- Start
- Mar 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifebemtinib in triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), ovarian cancer and 2 more (6 arms), sponsored by InxMed. Primary endpoints: Recommended Phase II Dose up to 6 Months and Objective Response Rate up to 24 Months. Started Mar 2022; status: completed.
02
Drugs
ifebemtinib
03
Conditions
triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)ovarian cancersmall cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT05830539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830539.